Press Releases

- MAR 04 2019
Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe
Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034. This patent covers the composition of matter for ONC206, its di-salt formulation, and its use in the treatment of cancer.

Read >
- FEB 25 2019
Oncoceutics and the National Cancer Institute Collaborate to Develop ONC206
Philadelphia, PA (February 22, 2019) – Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health (NIH) involving its imipridone family of anti-cancer compounds. ONC206 has been studied extensively for several years in models of central nervous system cancers, including high grade gliomas as evaluated by the laboratory of Mark

Read >

- FEB 15 2019
Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd.
Philadelphia, PA (February 15, 2019) – Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a

Read >
- JAN 14 2019
Oncoceutics Expands Patent Family to Include Use of ONC201 in H3 K27M-Mutant Gliomas
Philadelphia, PA (January 14, 2019) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a histone 3 K27M (H3 K27M) mutation. This patent extends the ONC201 patent life through at least 2038. This patent is the eighth

Read >

Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe